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Increased functional connectivity in the resting-state basal
ganglia network after acute heroin substitution
A Schmidt1,2, N Denier1, S Magon2,3, E-W Radue2, CG Huber1, A Riecher-Rossler1, GA Wiesbeck1, UE Lang1, S Borgwardt1,2,4 and
M Walter1
Reinforcement signals in the striatum are known to be crucial for mediating the subjective rewarding effects of acute drug intake. It
is proposed that these effects may be more involved in early phases of drug addiction, whereas negative reinforcement effects may
occur more in later stages of the illness. This study used resting-state functional magnetic resonance imaging to explore whether
acute heroin substitution also induced positive reinforcement effects in striatal brain regions of protracted heroin-maintained
patients. Using independent component analysis and a dual regression approach, we compared resting-state functional
connectivity (rsFC) strengths within the basal ganglia/limbic network across a group of heroin-dependent patients receiving both
an acute infusion of heroin and placebo and 20 healthy subjects who received placebo only. Subsequent correlation analyses were
performed to test whether the rsFC strength under heroin exposure correlated with the subjective rewarding effect and with
plasma concentrations of heroin and its main metabolites morphine. Relative to the placebo treatment in patients, heroin
signiﬁcantly increased rsFC of the left putamen within the basal ganglia/limbic network, the extent of which correlated positively
with patients’ feelings of rush and with the plasma level of morphine. Furthermore, healthy controls revealed increased rsFC of the
posterior cingulate cortex/precuneus in this network relative to the placebo treatment in patients. Our results indicate that acute
heroin substitution induces a subjective rewarding effect via increased striatal connectivity in heroin-dependent patients,
suggesting that positive reinforcement effects in the striatum still occur after protracted maintenance therapy.
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INTRODUCTION
The initial development of drug addiction is mainly driven by
pleasurable hedonic effects, which promote renewed drug intake
through positive reinforcement mechanisms.1–3 Experimental
evidence in animals revealed that the subjective rewarding effects
of acute drug intake are crucially mediated by reinforcement
signals in dopamine (DA)-innervated midbrain regions such as the
striatum.4,5 Imaging studies in humans have supported this
hypothesis by showing that drug intake acutely increased the
extracellular concentration of DA in the striatum and that these
increases were associated with their rewarding effects.6 That is,
the subjects who had the greatest striatal DA increases after acute
drug administration were the ones who experienced the
rewarding effects most intensely.7,8
Behavioral,9 electrophysiological10 and neurochemical11 evi-
dences from animal research have demonstrated that opiates also
activate the DA system, which is essential for their acute
rewarding effects.12 In more detail, heroin mainly exerts its effects
through μ- and κ-opiate receptor agonism; the μ-opiate receptor
subtype is critical for the rewarding effects of heroin and
morphine, because blockade of μ-opiate receptors, but not of
other receptors, attenuates opiate self-administration.13 The
heroin-induced striatal DA release is mediated through binding
the μ-opioid receptor of GABAergic cells, which is closely
associated with subjective rewarding.14 Activation of μ-opioid
receptors thus represents a key molecular trigger for the acute
rewarding effects of opiates.15
Most recent imaging studies have been using resting-state
functional magnetic resonance imaging (fMRI) to gain a mechan-
istic understanding of brain functions at the large-scale neural
system level. Resting-state functional connectivity (rsFC) is based
on the analysis of low-frequency ﬂuctuations present in the blood-
oxygenation-level-dependent signal.16 These low-frequency ﬂuc-
tuations have been shown to be temporally correlated within
spatially distinct but functionally related resting-state networks,17
establishing an intrinsic functional architecture.18 Resting-state
networks are associated with many known brain functions
including sensory, cognitive or reward processes.18,19 Thus,
evaluating resting-state networks can provide important informa-
tion regarding inherent brain function that may help identify
networks key to addiction-related behaviors, which may be
diagnostically or therapeutically useful. For instance, previous
resting-state fMRI studies have detected a basal ganglia/limbic
network during rest, which subsumes the striatum, the thalamus
and the amygdala.20,21 Many of these regions are strongly
implicated in reward processes and DA function,22 and a recent
imaging study revealed rsFC differences within this network
between nicotine-dependent smokers and healthy controls
(HCs).23 These evidences suggest that connectivity abnormalities
within the basal ganglia/limbic network may contribute to
aberrant rewarding effects in drug-dependent individuals.
This study used resting-state fMRI to explore how an acute
heroin treatment modulated rsFC within the basal ganglia/limbic
network and whether this change was related to the subjective
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rewarding effect induced by heroin. In particular, resting-state
connectivity strengths in this network were compared between 20
heroin-dependent patients after receiving both an acute infusion
of heroin and placebo and 20 healthy subjects who received
placebo only. Although all patients are actively enrolled in a
maintenance therapy, acute heroin substitution still induces
positive emotions and a feeling of rush in these patients,24,25
indicating that positive reinforcement effects continue during
protracted maintenance treatments. Here, we examined whether
these subjective rewarding effects after heroin substitution were
mediated via connectivity changes in the basal ganglia/limbic
network. Given that heroin26 and its psychoactive metabolite
morphine augmented DA release in the striatum of rodents,11,27,28
we additionally performed correlation analysis between plasma
levels of heroin and morphine and rsFC in the basal ganglia/limbic
network after heroin administration. We hypothesized that the
acute subjective heroin-induced reward effect (that is, feeling of
‘high’) was associated with increased rsFC within the basal
ganglia/limbic network compared with the placebo treatment in
patients and HCs.
MATERIALS AND METHODS
Participants
The study was approved by the local ethics committee and registered with
http://clinicaltrials.gov (ID NCT01174927). After receiving a written and oral
description of the aim of this study, all participants gave written informed
consent statements before inclusion.
Twenty outpatients with opioid dependence according to International
Classiﬁcation of Diseases (ICD)-10 criteria were recruited from the Centre of
Substance Use Disorders of the University Hospital of Psychiatry in Basel.
The included patients that were older than 18 years and had a past history
of intravenous heroin consumption with a current heroin-assisted
treatment for at least 6 months with an unchanged heroin dose during
the previous 3 months. Patients were excluded from participation
if they currently had additional physical diseases or a psychiatric disorder
including other comorbid conditions such as substance dependencies. We
did not exclude past history of psychiatric disorders or substance
dependence. Clinically experienced psychiatrists (MW) conducted a
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis II
Disorders Structured Clinical Interview for DSM Disorders (SCID-II) to assess
the diagnosis of comorbid personality disorders.
Twenty HCs were recruited from the general population by advertise-
ment in the same geographical area as patients. They were carefully
screened using a semi-structured clinical interview to exclude psychiatric
or physical illness or a family history of psychiatric illness. Analogous to the
inclusion criteria for patients, controls were also excluded if they had a
positive alcohol breathalyzer test, or any neurologic or severe medical
illness history. Owing to ethical reasons, HC only received placebo but no
heroin treatment.
Controls and patients were told to abstain from illicit drug consumption
for the duration of the study, as well as to abstain from alcohol intake 72 h
before scanning. Nevertheless, nine patients were tested positive for
cocaine at one or both points of the measurement. We have incorporated
this potential confounder into our analyses. Subjects’ characteristics are
summarized in Table 1.
Experimental design
Using a crossover, double-blind, vehicle-controlled design, placebo (saline)
and heroin (diacetylmorphine) were administered through an indwelling
intravenous catheter over a period of 30 s. Heroin hydrochloride was
dissolved on site in 5ml of sterile water and aspirated into a syringe as
previously described.29 Each patient was scanned twice, with a short
interval between scans (mean 9± 3.8 days). Subjects (10) who received
their individualized dose of heroin before the ﬁrst scanning session
received 5ml of placebo before the second session, and vice versa. To
preclude order effects, the application scenario was balanced so that 10
patients ﬁrst received heroin and then placebo, whereas in the other 10
patients the sequence was reversed. During both sessions all heroin-
dependent patients received both heroin and placebo. That is, the subjects
who received heroin before scanning were administered vehicle after
scanning (that is, 60 min after the ﬁrst injection), whereas the subjects who
received placebo before scanning were administered heroin after
scanning. HC participated only in the placebo condition.
Subjective heroin effects and bioanalytical measurements
Patients reported their feelings of rush, sedation and intoxication on a
visual analog scale (values ranging from 0 to 10) ~ 60min after treatment.
The plasma concentrations of heroin and morphine 3, 10 and 60min after
heroin administration have previously been reported.30 We brieﬂy report
here the measuring approach for the sake of completeness. The plasma
concentrations of morphine were measured in venous ammonium-
heparinized plasma and assessed using high-performance liquid chroma-
tography on a 125× 2-mm (inner diameter) Nucleosil 50 C-8 ec column
with a particle size of 5 μm and a 8× 3-mm (inner diameter) precolumn
packed with Nucleosil 120 C-8 and a particle size of 3 μm followed by
diode array detection. Sample preparation and instrumental conditions
were as described previously in detail.31
Resting-state fMRI
For the resting-state scan (5 min), subjects were instructed to lie in
dimmed light with their eyes open, to think of nothing in particular and
not to fall asleep.
Image acquisition
Scanning was performed on a 3T scanner (Siemens Magnetom Verio,
Siemens Healthcare, Erlangen, Germany) 20min post treatment. Whole-
brain functional imaging was performed using a gradient echo planar
imaging sequence (repetition time (TR) = 2000ms, echo time (TE) = 28ms,
ﬂip angle = 82°, ﬁeld of view=228× 228mm2, 32 slices, slice thickness:
3.3 mm; voxel size = 3.6 × 3.6 × 3.3 mm3). In total, 152 echo planar imaging
volumes were acquired. In addition, a high-resolution T1-weighted
magnetization prepared rapid acquisition gradient echo (MPRAGE) image
was acquired (TR = 2000ms; TE = 3.37ms; ﬂip angle = 8°; inversion
time= 1000ms; 176 slices; slice thickness = 1 mm; voxel
size = 1 × 1× 1mm3).
Table 1. Characteristics of healthy controls and heroin-dependent patients.
Healthy controls (n=20) Heroin-dependent patients (n= 20) Between-group statistics
Age (years± s.d.) 40.24± 10.91 41.45± 6.70 t(38)= 0.423; P= 0.675
Gender (women/men) 6/14 8/12 χ2= 0.440; P= 0.507
Education (years± s.d.) 14.25± 2.55 10.20± 2.82 t(38)= 4.764; P= 0.0001
Employment (yes/no) 20/0 10/10 χ2= 13.333; P= 0.0003
Smoker (yes/no) 20/0 20/0 NS
Cannabis consumption (yes/no) 5/15 6/14 χ2= 0.125; P= 0.723
Cocaine consumption (yes/no) 0/20 9/11 χ2= 11.613; P= 0.007
Age at ﬁrst-time heroin use (years± s.d.) — 18.9± 3.50 —
Duration of dependence (years± s.d.) — 21.5± 6.10 —
Daily heroin dose (mg± s.d.) — 290± 121.44 —
Abbreviation: NS, not signiﬁcant.
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Functional connectivity analysis
In a ﬁrst step, resting-state analysis was carried out using MELODIC
(Multivariate Exploratory Linear Optimized Decomposition into Indepen-
dent Components),19 a part of FMRIB Software Library (www.fmrib.ox.ac.
uk/fsl). MELODIC is a powerful data-driven model-free approach for ﬁnding
independent patterns in multivariate data (that is, resting-state networks
such as the basal ganglia/limbic network). Preprocessing consisted of
motion correction using MCFLIRT (Motion Correction using FMRIB's Linear
Image Registration Tool),32 removal of non-brain tissue with the Brain
Extraction Tool,33 spatial smoothing using a 5-mm full-width-at-half-
maximum Gaussian kernel and high-pass temporal ﬁltering equivalent to
111.1 s. Registration of the functional echo planar imaging volumes to each
individual subject’s high-resolution MPRAGE image and registration of the
MPRAGE data to the standard space template (Montreal Neurological
Institute, MNI152 T1 1mm3) were both done using FLIRT. Preprocessed
functional data containing 152 time points for each subject were
temporally concatenated across subjects to create a single four-
dimensional data set. The data set was decomposed into independent
components, with a free estimation for the number of components. The
components of interest were selected by visual inspection based on
previous literature19,34 and the frequency spectra of the time courses of
the components. We used an equal number of subjects from each group
so as not to skew independent components in favor of a particular
population/treatment. In this study, group-independent component
analysis was used to identify the basal ganglia/limbic network.
This network has been previously noted in other resting-state fMRI
studies using independent component analysis20,21 including studies in
drug addiction.23 A dual regression approach35 with nonparametric
permutation (5000) tests (randomize,36 FMRIB Software Library) were
carried out to detect statistically signiﬁcant differences among treatments
(placebo vs heroin in patients) and groups (HC vs patients) within the
boundaries of the spatial map (basal ganglia/limbic network) obtained
with group-independent component analysis (Figure 1). Finally, a family-
wise error correction for multiple comparisons was performed, implement-
ing threshold-free cluster enhancement using a signiﬁcance threshold of
Po0.05.37
RESULTS
Subjective heroin effects and plasma levels
These data have been previously published.24,30,38 We adapted
them to the subjects who completed resting-state fMRI scanning.
Subjective feelings of rush (t(19) = 9.570, P= 0.0001), sedation (t
(19) = 2.111, P= 0.049) and intoxication (t(19) = 4.040, P= 0.0008)
were signiﬁcantly higher after heroin than placebo administration
(Figure 2a). Measurements of heroin’s and morphine’s plasma
concentrations indicated the much longer half-life period of
morphine compared with acetylated compounds.39 Although
heroin’s plasma concentration rapidly decreased from 800 ng -
ml− 1 (s.d.: 655) to 170 ngml− 1 (s.d.: 236) and 13 ngml− 1 (s.d.: 31)
at 3, 10 and 60min after heroin injection, the mean concentrations
of morphine decreased from 332 ngml− 1 (s.d.: 117) to 296 -
ngml− 1 (s.d.: 114) and 220 ngml− 1 (s.d.: 89). Plasma concentra-
tions of heroin and morphine are depicted in Figure 2b.
Figure 1. Spatial maps representing the basal ganglia/limbic network during resting state detected by group-independent component
analysis for (a) healthy controls, (b) heroin-dependent patients after heroin and (c) placebo administration. Maps were created using a one-
sample t-test for each condition (family-wise error-corrected at P= 0.001). Regions belonging to this network include the entire striatum,
thalamus and amygdala. The right side of the brain is displayed on the right side of the ﬁgure. Color bars represent signal intensity (one-P-
value) (obtained from the one-sample t-test).
rsFC after acute heroin substitution
A Schmidt et al
3
Translational Psychiatry (2015), 1 – 8
Functional resting-state connectivity results
Dual regression of the basal ganglia/limbic network identiﬁed with
group-independent component analysis (Figure 1) revealed
increased rsFC of the left putamen within this network in patients
after heroin administration compared with the placebo treatment
(family-wise error-corrected) (Figure 3a). Importantly, this heroin-
induced increase in rsFC of the left putamen relative to placebo
did not depend on whether the patients were positive tested for
cocaine or not (t(18) = 1.075, P= 0.297). There were no regions
where the placebo treatment showed increased rsFC to the
network compared with the heroin treatment. No difference
between HC and the heroin treatment in patients was found, but
HC revealed increased rsFC of the posterior cingulate cortex (PCC)/
precuneus in the basal ganglia/limbic network relative to the
placebo treatment in patients (family-wise error-corrected)
(Figure 3b).
Relation of functional connectivity, subjective heroin effect and
plasma levels
We further tested by using Pearson correlation whether the
degree of rsFC strength of the left putamen under heroin
exposure correlated with subjective heroin effects (intoxication,
rush and sedation) and with plasma levels of heroin and morphine
10min after heroin administration (nearest time point to resting-
state recording). Bonferroni correction was used to adjust for
multiple testing. On the basis of previous resting-state fMRI
evidence showing a relation between the left putamen and the
duration of heroin use in abstinent heroin-dependent subjects,40
we also tested whether rsFC strengths of the left putamen after
placebo exposure was related to the duration of heroin
dependence. The FC strength of the left putamen within the
basal ganglia/limbic network was indexed by parameter estimates
(z-scaled) only of the signiﬁcant voxels obtained from the heroin
vs placebo comparison in patients (cf. Figure 3a).
The rsFC strength after heroin injection positively correlated
with the plasma level of morphine (r= 0.480, P= 0.032, uncor-
rected for multiple comparisons) but not of heroin (r=− 0.267,
P= 0.255) (Figure 4a). Furthermore, we found a signiﬁcant positive
correlation between the FC strength of the left putamen within
the basal ganglia/limbic network under heroin exposure and the
subjectively perceived feeling of ‘rush’ (r= 0.507, P= 0.023,
uncorrected for multiple testing), but not with feelings of sedation
(r=− 0.113, P= 0.635) or intoxication (r=− 0.016, P= 0.947)
(Figure 4b). Finally, there was a signiﬁcant negative correlation
between the rsFC strength after placebo treatment and years of
dependence (r= -0.552, P= 0.012) (Figure 4c).
DISCUSSION
This study explored the neural mechanism underlying heroin’s
acute subjective rewarding effect in protracted heroin-dependent
patients. In particular, we investigated how acute heroin substitu-
tion modulated rsFC within the basal ganglia/limbic network and
whether this change was related to the subjective rewarding
effect induced by heroin. We found that heroin acutely increased
rsFC of the left putamen within the basal ganglia/limbic network
compared with the placebo treatment in heroin-dependent
patients. Notably, the extent of rsFC strength of the left putamen
after heroin administration correlated positively with the sub-
jective experience of rush and with the plasma levels of heroin’s
main psychoactive metabolite morphine. Furthermore, we found
that HCs had increased rsFC of the PCC/precuneus in this network
relative to the placebo treatment in patients. We discuss these
ﬁndings in the following within a positive reinforcement frame-
work of reward processing in drug addiction1,41 and infer on the
basis of this perspective a possible neuropharmacological
mechanism for the subjective rewarding effect of heroin.
Reinforcement signals in the striatum are known to be crucial
for the rewarding effect of heroin and thus have a key role in the
development of opioid dependence.5 In accordance with this, our
results show that acute heroin administration increased rsFC of
the left putamen in the basal ganglia/limbic network compared
with the placebo treatment, whereas the extent of left putamen
connectivity under heroin exposure correlated with patients’
feelings of rush. Remarkably, this relation was speciﬁc for the
euphoric effect of the drug and not for its sedative and intoxicant
effect, albeit this correlation did not survive after correcting for
multiple testing. Nevertheless, this ﬁnding is in line with a
previous fMRI study, which revealed an association between
putamen activity and the pleasurable relaxation and enjoyment of
cigarette smoking.42 It is interesting to note that acute heroin
administration selectively exerted its effect on the left, but not
right putamen connectivity. This hemispheric asymmetry is in line
with previous evidence showing that intravenous injection of μ-
opioid agonist induces left-lateralized brain activation, which
correlated with the euphoric effect of the drug.43 However, more
evidence is needed to conﬁrm this laterality effect of acute heroin
substitution.
It is further emphasized that drugs of abuse increase striatal DA
concentrations and that these increases were associated with their
reinforcing effects.6 For instance, amphetamine-induced DA
release in the human ventral striatum correlates with euphoria,7
whereas subjects having the greatest DA increases after methyl-
phenidate intake were those that perceived the most intense
‘high’.8 Increased striatal DA levels have also been implicated in
the rewarding and locomotor-stimulatory properties of morphine
Figure 2. (a) Self-reported psychological heroin effects. Heroin
signiﬁcantly increased feelings of intoxication, rush and sedation
relative to the placebo treatment. Note: signiﬁcant differences
between treatment conditions at *Po0.05 and at **Po0.001. (b)
Plasma concentrations of heroin (diacetylmorphine) and its main
psychoactive metabolite morphine 3, 10 and 60min after heroin
injection. Means and s.e. are displayed.
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in animals,41,44 likely mediated via major dopaminergic projec-
tions from the substantia nigra and the ventral tegmental area.5 In
more detail, the morphine-evoked DA release is considered to be
due to inhibition of the inhibitory GABAergic interneurons in the
ventral tegmental area through activation of μ-opioid receptors to
activate mesocorticolimbic dopaminergic neurons.4,45 According
to this evidence, it is conceivable that our ﬁnding of increased
putamen connectivity after heroin administration was mediated at
least in part through heroin-induced DA release into the striatum.
This interpretation is supported by the correlation between
morphine’s plasma level and left putamen connectivity under
heroin exposure, having in mind that morphine evokes DA in the
striatum.11,46 That is, patients revealing the greatest morphine
plasma concentrations 10 min after heroin injection showed the
strongest putamen connectivity to the basal ganglia/limbic
network, which subsumes the entire striatum, thalamus and
amygdala. The putative striatal DA release after acute heroin
injection resonances with evidence showing that detoxiﬁed heroin
users have lower DA transporter availability that in turn leads to
increased DA levels.47
Baseline differences in striatal DA levels might also explain why
heroin only increased rsFC of the left putamen compared with the
placebo treatment in patients, but not compared with HCs. In
particular, chronic heroin-dependent subjects have lower striatal
D2 receptor availability and low presynaptic DA compared with
HCs48,49 (see Hou et al.14 for a comprehensive review on the DA
system in heroin addiction). Supportive, acute states of with-
drawal, as in this study reﬂected by the placebo condition,50 have
been associated with decreased striatal DA level.51 Therefore, we
might speculate that the placebo treatment in our study
(experimentally induced state of acute withdrawal50) was
accompanied by lower levels of striatal DA compared with HCs,
resulting in a more pronounced difference of striatal DA level
compared with the DA level induced by acute heroin treatment.
Furthermore, we found that the left putamen connectivity
within the basal ganglia/limbic network after placebo treatment
correlated negatively with the duration of heroin use, perhaps
reﬂecting disease-related long-term effects on reward-related
pathways. In line with this results, previous resting-state fMRI
studies have already highlighted the importance of the putamen
for the pathophysiology of heroin addiction by showing that
decreased FC of the putamen,52 as well as abnormal topological
properties of the left putamen as indicated by graph metrics (that
is, the shortest absolute path length) were negatively related to
the duration of heroin dependence.40 Furthermore, it has also
been shown that D2 receptor availability in the putamen
correlated negatively with years of opiate use in recently abstinent
opiate-dependent subjects.48 These changes in the neural reward
system may be part of functional alterations, besides those on the
brain stress system, postulated to underlie the chronic relapsing
nature of prescription opioid addiction.53,54
However, although acute heroin injection induced DA release in
rats,26 several imaging studies in humans failed to detected striatal
DA release induced by acute heroin administration55–57 or by the
expectation of heroin reward.58 This can either be explained by
the small patient samples used in these studies, the limited
sensitivity of the applied technologies or because activation of the
dopaminergic system is not necessarily critical for the rewarding
effects of heroin.4,59,60 The hypothesis that the positive reinforce-
ment effect of acute heroin injection is not directly mediated by
DA is supported by studies showing that neurochemically speciﬁc
lesions of DA in the nucleus accumbens with 6-hydroxydopamine
Figure 3. Dual regression results. (a) Results of the comparison between the placebo and heroin treatment in heroin-dependent patients. The
left putamen demonstrates greater functional connectivity (FC) within the basal ganglia/limbic network after the heroin compared with the
placebo treatment (family-wise error (FWE) corrected at Po0.05) (peak maxima of cluster 1: x=− 26, y=–10 and z= 8; cluster 2: x=− 26, y= 2
and z= 8 and cluster 3: x=− 26, y= 2 and z=− 4). (b) Results between healthy controls and patients after placebo administration. The
posterior cingulate cortex/precuneus (peak maxima: x= 17, y=− 46 and z= 38) demonstrates greater resting-state functional connectivity
within the basal ganglia/limbic network in healthy controls compared with the placebo treatment in patients (FWE-corrected at Po0.05). The
right side of the brain is displayed on the right side of the ﬁgure. Color bars represent signal intensity (one–P-value) (obtained from the paired
t-test (a) and the two-sample t-test (b), respectively).
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failed to block heroin self-administration.61 It has also been shown
that DA is not required for morphine-induced reward as measured
by conditioned place preference.62
Finally, we also found that HCs had increased rsFC of the PCC/
precuneus in the basal ganglia/limbic network relative to the
placebo treatment in patients. Decreased FC of the PCC and
thalamus to different brain regions has previously been found in
heroin abusers.63 A recent study suggests that high impulsive
smokers have greater difﬁculty in controlling their cravings, and
that this weakness may be mediated by lower PCC activity.64 It has
also been shown that positive emotionality correlated positively
with activity in the precuneus and PCC65 and that they activate
with just the presence of an immediate reward,66 a mechanism
that is likely related to positive emotional feelings. Given that the
placebo treatment in this study represents an acute state of
withdrawal characterized by high levels of craving, anxiety and
stress hormone releases,50 the reduced PCC/precuneus connec-
tivity might have partly contributed to this negative emotional
state. In accordance with this view, metabolic activity of the
ventral striatum tended to be negatively correlated with with-
drawal symptoms, including craving, negative effect and somatic
anxiety symptoms in nicotine-dependent subjects.42
This study has limitations that may inﬂuence the interpretation
of our ﬁndings. We acknowledge the lack of a direct measure of
DA concentration induced by acute heroin administration, which
aggravates inferences about the underlying neuropharmacologi-
cal mechanism induced by μ-opioid receptor agonism. Thus,
further research is needed to understand the subjective rewarding
effects of acute heroin administration by unifying different levels
starting from μ-opioid receptor binding to effects of this binding
on neurotransmitter pathways and further to the neural system
level. Furthermore, we cannot exclude effects on vasoactivity
induced by heroin,67 which might have confounded our results.
We have also not considered physiological noise that may
increase the risk for false positives in pharmacological resting-
state fMRI analysis.68 Finally, although differences in formal
education may have confounded the comparisons between
patients and HCs, this could not account for the differences
between the heroin and placebo treatment among patients.
In summary, our ﬁndings indicate that increased rsFC of the
putamen may contribute to the subjective rewarding effect of
heroin and thus provide evidence at the large-scale neural system
level of how continued heroin consumption is motivated through
positive reinforcement effects. Notably, this positive reinforcement
effect was found in heroin-maintained patients. Although it has
been proposed that the initial phase of drug addiction is
dominated by positive reinforcement mechanisms and that
antireward processes (that is, negative reinforcement) increase
over the duration of the dependence,69,70 our data suggest that
acute heroin substitution in long-lasting patients still induces a
positive reinforcement effect in the striatum. We have recently
shown that acute heroin substitution in these patients also led to a
negative reinforcement effect by reducing state-anxiety and stress
hormone responses, an effect that was mediated through reduced
Figure 4. (a) Signiﬁcant positive correlation between resting-state functional connectivity (rsFC) strength of the left putamen and morphine’s
plasma level 10min after heroin injection (r= 0.480, P= 0.032). (b) Positive correlation between rsFC strength under heroin exposure and
subjective feelings of ‘rush’ (r= 0.507, P= 0.023). Importantly, no correlation was found with heroin-induced feelings of sedation (r=− 0.113,
P= 0.635) or intoxication (r=− 0.016, P= 0.947). (c) Signiﬁcant negative correlation between the rsFC strength following placebo treatment
and years of heroin dependence (r=− 0.552, P= 0.012).
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amygdala activity and connectivity.38,71 These studies together
indicate that both positive and negative reinforcement mechan-
isms still occur after protracted heroin maintenance therapy. The
prescription of pharmaceutical heroin has repeatedly been found
to be an effective treatment for severe heroin addiction72–74 and
for heroin addicts who have failed to beneﬁt from methadone
maintenance treatment.75 However, although heroin substitution
strategies can successfully reduce harm and criminality, as well as
the additional intake of heroin besides the daily substitution
doses,73,74 this study also shows that heroin-assisted treatment
further drives the addiction circle by inducing a positive
reinforcement effect. In general, neuroimaging and pychophar-
macological imaging needs to translate results in the clinical ﬁeld,
targeting clinical outcomes including response to preventive
interventions.76 This additionally impedes withdrawal and absti-
nence efforts from opioid consumption and should be considered
in substitution therapies. However, the relative importance of
positive and negative reinforcement mechanisms for the transi-
tion from early to late phases of drug addiction is currently being
discussed controversially.2 Future research is thus needed to gain
a better understanding of the reinforcement mechanisms under-
lying the development and maintenance of heroin addiction. This
study demonstrates that the assessment of resting-state fMRI is a
promising technique for this purpose.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGMENTS
We would like to acknowledge the infrastructural support of the Medical Image
Analysis Center, University Hospital Basel. This study was supported by the Swiss
National Science Foundation (32003B-127544) (MW and SB) and FAG Basel (AS).
REFERENCES
1 Wise RA. Neurobiology of addiction. Curr Opin Neurobiol 1996; 6: 243–251.
2 Wise RA, Koob GF. The development and maintenance of drug addiction. Neu-
ropsychopharmacology 2014; 39: 254–262.
3 Robinson TE, Berridge KC. Addiction. Annu Rev Psychol 2003; 54: 25–53.
4 Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of
reward-related learning and memory. Annu Rev Neurosci 2006; 29: 565–598.
5 Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology
2010; 35: 217–238.
6 Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and
addiction: results from imaging studies and treatment implications. Mol Psychiatry
2004; 9: 557–569.
7 Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA et al.
Amphetamine-induced dopamine release in human ventral striatum correlates
with euphoria. Biol Psychiatry 2001; 49: 81–96.
8 Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C et al. Reinforcing
effects of psychostimulants in humans are associated with increases in brain
dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 1999; 291:
409–415.
9 Holmes LJ, Bozarth MA, Wise RA. Circling from intracranial morphine applied to
the ventral tegmental area in rats. Brain Res Bull 1983; 11: 295–298.
10 Matthews RT, German DC. Electrophysiological evidence for excitation of rat
ventral tegmental area dopamine neurons by morphine. Neuroscience 1984; 11:
617–625.
11 Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic
dopamine concentrations in the mesolimbic system of freely moving rats. Proc
Natl Acad Sci USA 1988; 85: 5274–5278.
12 Bozarth MA, Wise RA. Heroin reward is dependent on a dopaminergic substrate.
Life Sci 1981; 29: 1881–1886.
13 De Vries TJ, Shippenberg TS. Neural systems underlying opiate addiction. J Neu-
rosci 2002; 22: 3321–3325.
14 Hou H, Tian M, Zhang H. Positron emission tomography molecular imaging of
dopaminergic system in drug addiction. Anat Rec (Hoboken) 2012; 295: 722–733.
15 Contet C, Kieffer BL, Befort K. Mu opioid receptor: a gateway to drug addiction.
Curr Opin Neurobiol 2004; 14: 370–378.
16 Biswal BB, Mennes M, Zuo XN, Gohel S, Kelly C, Smith SM et al. Toward discovery
science of human brain function. Proc Natl Acad Sci USA 2010; 107: 4734–4739.
17 Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human
brain is intrinsically organized into dynamic, anticorrelated functional networks.
Proc Natl Acad Sci USA 2005; 102: 9673–9678.
18 Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, Mackay CE et al. Correspondence
of the brain's functional architecture during activation and rest. Proc Natl Acad Sci
USA 2009; 106: 13040–13045.
19 Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state
connectivity using independent component analysis. Philos Trans R Soc Lond B
Biol Sci 2005; 360: 1001–1013.
20 Cole DM, Beckmann CF, Searle GE, Plisson C, Tziortzi AC, Nichols TE et al. Orbi-
tofrontal connectivity with resting-state networks is associated with midbrain
dopamine D3 receptor availability. Cereb Cortex 2012; 22: 2784–2793.
21 Moussa MN, Steen MR, Laurienti PJ, Hayasaka S. Consistency of network modules
in resting-state FMRI connectome data. PLoS One 2012; 7: e44428.
22 Sesack SR, Grace AA. Cortico-basal ganglia reward network: microcircuitry. Neu-
ropsychopharmacology 2010; 35: 27–47.
23 Janes AC, Nickerson LD, Frederick BEB, Kaufman MJ. Prefrontal and limbic resting
state brain network functional connectivity differs between nicotine-dependent
smokers and non-smoking controls. Drug Alcohol Depend 2012; 125: 252–259.
24 Denier N, Gerber H, Vogel M, Klarhöfer M, Riecher-Rossler A, Wiesbeck GA et al.
Reduction in cerebral perfusion after heroin administration: a resting state arterial
spin labeling study. PLoS One 2013; 8: e71461.
25 Blum J, Gerber H, Gerhard U, Schmid O, Petitjean S, Riecher-Rössler A et al. Acute
effects of heroin on emotions in heroin-dependent patients. Am J Addict 2013; 22:
598–604.
26 Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of meso-
limbic dopamine transmission by a common mu1 opioid receptor mechanism.
Science 1997; 276: 2048–2050.
27 Nakagawa T, Suzuki Y, Nagayasu K, Kitaichi M, Shirakawa H, Kaneko S. Repeated
exposure to methamphetamine, cocaine or morphine induces augmentation of
dopamine release in rat mesocorticolimbic slice co-cultures. PLoS One 2011; 6:
e24865.
28 Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdère P, Caccia S et al. 5-
HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced
in vivo by amphetamine and morphine in both the rat nucleus accumbens and
striatum. Neuropsychopharmacology 2002; 26: 311–324.
29 Stohler R, Dürsteler KM, Störmer R, Seifritz E, Hug I, Sattler-Mayr J et al. Rapid
cortical hemoglobin deoxygenation after heroin and methadone injection in
humans: a preliminary report. Drug Alcohol Depend 1999; 57: 23–28.
30 Walter M, Denier N, Gerber H, Schmid O, Lanz C, Brenneisen R et al. Orbitofrontal
response to drug-related stimuli after heroin administration. Addict Biol 2014:
doi: 10.1111/adb.12145.
31 Bourquin D, Bundeli P, Lehmann T, Brenneisen R. Diacetylmorphine and its
metabolites in plasma by HPLC with diode-array and atmospheric pressure
ionization mass spectrometric detection. J Liq Chrom Rel Technol 1999; 22:
2663–2674.
32 Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust
and accurate linear registration and motion correction of brain images. Neuro-
image 2002; 17: 825–841.
33 Smith SM. Fast robust automated brain extraction. Hum Brain Mapp 2002; 17:
143–155.
34 Damoiseaux JS, Rombouts SA, Barkhof F, Scheltens P, Stam CJ, Smith SM et al.
Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci USA
2006; 103: 13848–13853.
35 Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM et al.
Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele.
Proc Natl Acad Sci USA 2009; 106: 7209–7214.
36 Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroi-
maging: a primer with examples. Hum Brain Mapp 2002; 15: 1–25.
37 Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems
of smoothing, threshold dependence and localisation in cluster inference. Neu-
roimage 2009; 44: 83–98.
38 Schmidt A, Walter M, Gerber H, Seifritz E, Brenneisen R, Wiesbeck GA et al.
Normalizing effect of heroin maintenance treatment on stress-induced brain
connectivity. Brain 2014; 138: 217–228.
39 Skopp G, Ganssmann B, Cone EJ, Aderjan R. Plasma concentrations of heroin and
morphine-related metabolites after intranasal and intramuscular administration. J
Anal Toxicol 1997; 21: 105–111.
40 Yuan K, Qin W, Liu J, Guo Q, Dong M, Sun J et al. Altered small-world brain
functional networks and duration of heroin use in male abstinent heroin-
dependent individuals. Neurosci Lett 2010; 477: 37–42.
41 Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol 1989; 40:
191–225.
rsFC after acute heroin substitution
A Schmidt et al
7
Translational Psychiatry (2015), 1 – 8
42 Rose JE, Behm FM, Salley AN, Bates JE, Coleman RE, Hawk TC et al. Regional brain
activity correlates of nicotine dependence. Neuropsychopharmacology 2007; 32:
2441–2452.
43 Schlaepfer TE, Strain EC, Greenberg BD, Preston KL, Lancaster E, Bigelow GE et al.
Site of opioid action in the human brain: mu and kappa agonists' subjective and
cerebral blood ﬂow effects. Am J Psychiatry 1998; 155: 470–473.
44 Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms
of memory. Neuron 2000; 25: 515–532.
45 Nestler EJ. Molecular mechanisms of drug addiction. J Neurosci 1992; 12: 2439–2450.
46 Smith JE, Co C, Freeman ME, Sands MP, Lane JD. Neurotransmitter turnover in rat
striatum is correlated with morphine self-administration. Nature 1980; 287: 152–154.
47 Jia SW, Wang W, Liu Y, Wu ZM. Neuroimaging studies of brain corpus striatum
changes among heroin-dependent patients treated with herbal medicine, U'ﬁner
capsule. Addict Biol 2005; 10: 293–297.
48 Zijlstra F, Booij J, van den Brink W, Franken IH. Striatal dopamine D2 receptor
binding and dopamine release during cue-elicited craving in recently abstinent
opiate-dependent males. Eur Neuropsychopharmacol 2008; 18: 262–270.
49 Martinez D, Saccone PA, Liu F, Slifstein M, Orlowska D, Grassetti A et al. Deﬁcits in
dopamine D(2) receptors and presynaptic dopamine in heroin dependence:
commonalities and differences with other types of addiction. Biol Psychiatry 2012;
71: 192–198.
50 Schmidt A, Borgwardt S, Gerber H, Wiesbeck GA, Schmid O, Riecher-Rössler A
et al. Acute effects of heroin on negative emotional processing: relation of
amygdala activity and stress-related responses. Biol Psychiatry 2013; 76: 289–296.
51 Melis M, Spiga S, Diana M. The dopamine hypothesis of drug addiction:
hypodopaminergic state. Int Rev Neurobiol 2005; 63: 101–154.
52 Upadhyay J, Maleki N, Potter J, Elman I, Rudrauf D, Knudsen J et al. Alterations in
brain structure and functional connectivity in prescription opioid-dependent
patients. Brain 2010; 133: 2098–2114.
53 Kreek MJ, Levran O, Reed B, Schlussman SD, Zhou Y, Butelman ER. Opiate
addiction and cocaine addiction: underlying molecular neurobiology and
genetics. J Clin Invest 2012; 122: 3387–3393.
54 Kreek MJ. Opiates, opioids and addiction. Mol Psychiatry 1996; 1: 232–254.
55 Daglish MR, Williams TM, Wilson SJ, Taylor LG, Eap CB, Augsburger M et al. Brain
dopamine response in human opioid addiction. Br J Psychiatry 2008; 193: 65–72.
56 Cosgrove KP, Tellez-Jacques K, Pittman B, Petrakis I, Baldwin RM, Tamagnan G
et al. Dopamine and serotonin transporter availability in chronic heroin users: a
[¹23I]β-CIT SPECT imaging study. Psychiatry Res 2010; 184: 192–195.
57 Kosel M, Noss RS, Hämmig R, Wielepp P, Bundeli P, Heidbreder R et al. Cerebral
blood ﬂow effects of acute intravenous heroin administration. Eur Neuropsycho-
pharmacol 2008; 18: 278–285.
58 Watson BJ, Taylor LG, Reid AG, Wilson SJ, Stokes PR, Brooks DJ et al. Investigating
expectation and reward in human opioid addiction with [(11) C]raclopride PET.
Addict Biol 2013; 19: 1032–1040.
59 Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward
pathways. Trends Pharmacol Sci 1992; 13: 177–184.
60 Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci
2005; 8: 1445–1449.
61 Le Moal M, Koob GF. Drug addiction: pathways to the disease and pathophy-
siological perspectives. Eur Neuropsychopharmacol 2007; 17: 377–393.
62 Hnasko TS, Sotak BN, Palmiter RD. Morphine reward in dopamine-deﬁcient mice.
Nature 2005; 438: 854–857.
63 Wang W, Wang YR, Qin W, Yuan K, Tian J, Li Q et al. Changes in functional
connectivity of ventral anterior cingulate cortex in heroin abusers. Chin Med J
(Engl) 2010; 123: 1582–1588.
64 Bourque J, Mendrek A, Dinh-Williams L, Potvin S. Neural circuitry of impulsivity in
a cigarette craving paradigm. Front Psychiatry 2013; 4: 67.
65 Volkow ND, Tomasi D, Wang GJ, Fowler JS, Telang F, Goldstein RZ et al. Positive
emotionality is associated with baseline metabolism in orbitofrontal cortex and in
regions of the default network. Mol Psychiatry 2011; 16: 818–825.
66 Albrecht K, Volz KG, Sutter M, von Cramon DY. What do I want and when do I
want it: brain correlates of decisions made for self and other. PLoS One 2013; 8:
e73531.
67 Honey G, Bullmore E. Human pharmacological MRI. Trends Pharmacol Sci 2004; 25:
366–374.
68 Khalili-Mahani N, Chang C, van Osch MJ, Veer IM, van Buchem MA, Dahan A et al.
The impact of ‘physiological correction’ on functional connectivity analysis of
pharmacological resting state fMRI. Neuroimage 2013; 65: 499–510.
69 Koob GF. Negative reinforcement in drug addiction: the darkness within. Curr
Opin Neurobiol 2013; 23: 559–563.
70 Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and the tran-
sition to drug dependence. Am J Psychiatry 2007; 164: 1149–1159.
71 Schmidt A, Borgwardt S, Gerber H, Wiesbeck GA, Schmid O, Riecher-Rössler A
et al. Acute effects of heroin on negative emotional processing: relation of
amygdala activity and stress-related responses. Biol Psychiatry 2014; 76:
289–296.
72 van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree
JM. Medical prescription of heroin to treatment resistant heroin addicts: two
randomised controlled trials. BMJ 2003; 327: 310.
73 Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted
treatment for opioid dependence: randomised controlled trial. Br J Psychiatry
2007; 191: 55–62.
74 Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A et al. Diace-
tylmorphine versus methadone for the treatment of opioid addiction. N Engl J
Med 2009; 361: 777–786.
75 Blanken P, Hendriks VM, van Ree JM, van den Brink W. Outcome of long-term
heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in
the Netherlands. Addiction 2010; 105: 300–308.
76 Borgwardt S, Fusar-Poli P. Third-generation neuroimaging in early schizophrenia:
translating research evidence into clinical utility. Br J Psychiatry 2012; 200:
270–272.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 International License. The images or
other third party material in this article are included in the article’s Creative Commons
license, unless indicatedotherwise in the credit line; if thematerial is not included under
the Creative Commons license, users will need to obtain permission from the license
holder to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
rsFC after acute heroin substitution
A Schmidt et al
8
Translational Psychiatry (2015), 1 – 8
